Athyrium to invest $1.23bn in near-commercial companies
This article was originally published in Scrip
Can't find a partner to help commercialize your Phase III drug awaiting US FDA approval? Athyrium Capital Management has raised its second fund in hopes of investing $1.23bn in such an opportunity.
You may also be interested in...
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.